Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on August 9, 2006
Japanese Journal of Clinical Oncology 2006 36(8):477-482; doi:10.1093/jjco/hyl074
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
36/8/477    most recent
hyl074v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fujisaka, Y.
Right arrow Articles by Saijo, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujisaka, Y.
Right arrow Articles by Saijo, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2006 Foundation for Promotion of Cancer Research

Pharmacokinetics and Pharmacodynamics of Weekly Epoetin Beta in Lung Cancer Patients

Yasuhito Fujisaka, Tomohide Tamura, Yuichiro Ohe, Hideo Kunitoh, Ikuo Sekine, Noboru Yamamoto, Hiroshi Nokihara, Atsushi Horiike, Tetsuro Kodama and Nagahiro Saijo

Division of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan

For reprints and all correspondence: Tomohide Tamura, Division of Internal Medicine, National Cancer Center Hospital, 5-1-1, Tsukiji Chuo-ku, Tokyo 104-0045, Japan. E-mail: ttamura{at}ncc.go.jp

Received December 16, 2005; accepted April 26, 2006

Background: To assess the pharmacokinetic profile and time-course of trough concentrations and hemoglobin levels associated with subcutaneous weekly administration of epoetin beta in lung cancer patients with chemotherapy-induced anemia.

Methods: Epoetin beta was subcutaneously administered to 15 anemic lung cancer patients once weekly for 8 weeks at doses of 9000, 18 000 and 36 000 IU. Pharmacokinetic parameters (Cmax, AUCinf and T1/2) were determined after the first single dose administration on a model-independent basis, and the relationship between the dose and these parameters was examined for linearity.

Results: Weekly administration of epoetin beta at 9000, 18 000 and 36 000 IU produced Cmax values of 308 ± 117 (mean ± standard deviation), 678 ± 86.7 and 1316 ± 766 mIU/ml, and AUCinf values of 15 300 ± 9524, 54 574 ± 16 265 and 88 501 ± 55 687 hr mIU/ml, respectively, showing dose-proportional increases. Trough concentrations tended to increase in the presence of severe bone marrow suppression induced by chemotherapy or other factors. Extremely high values were seen in three patients, but there was no apparent trend toward an increase with repeated doses. After 8 weeks’ administration at 9000, 18 000 and 36 000 IU, hemoglobin levels were changed by –0.37 ± 1.26, 2.15 ± 1.36 and 2.82 ± 2.17 g/dl, respectively.

Conclusions: Epoetin beta exhibited linear pharmacokinetics when administered to anemic cancer patients at weekly doses of 9000–36 000 IU and did not cause drug accumulation. Hemoglobin levels increased with weekly doses of 18 000 or 36 000 IU.

Key Words: anemia • epoetin beta • pharmacokinetics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.